Clinical Study on the Prevention and Treatment of Postoperative Metastasis of Lung Cancer by Fuzheng Quxie Recipe
NCT06381960 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 356
Last updated 2024-05-03
Summary
To address the clinical challenge of postoperative metastasis in stage IIA-IIIA non-small cell lung cancer with negative driver gene expression, there is a lack of effective diagnostic and therapeutic measures. Based on this, investigators propose to carry out a clinical study on the prevention and treatment of postoperative metastasis of IIA-IIIA stage lung cancer with negative driver gene expression with the formula of supporting the positive and dispelling the evil.
Conditions
Interventions
- DRUG
-
Fuzheng Quxie Recipe
Treatment group: Fuzheng Quxie Recipe (Yifei Sanjie Recipe) ingredients: Sheng Huang Qi 15g, Jiao Bai Zhu 15g, Bai Fu Ling 15g, Bei Sha Shen 15g, Zhe Mai Dong 15g, Dang Shen 15g, Shu Yang Quan 15g, Xia Ku Cao 15g, Sheng Mu Li 15g, Shi Jian Chuan 15g, Shi Shang Bai 15g, and Hai Zao 15g. Combined with basic chemotherapy after lung cancer.
- DRUG
-
Fuzhengquye Fang Recipe simulant
Control group: Fuzhengquye Fang Recipe simulant, which was prepared into control group placebo drug according to 5% of the drug content in the treatment group. Combined with basic chemotherapy after lung cancer.
Sponsors & Collaborators
-
Jianhui Tian
lead OTHER
Principal Investigators
-
Jianhui Tian, professor · Shanghai University of Traditional Chinese Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-01
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
NCT06534489 ·Status: RECRUITING
-
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
NCT06183762 ·Status: RECRUITING
-
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
NCT06198868 ·Status: RECRUITING
-
CTC in Lung Caner Patients With Bone Metastases
NCT04568291 ·Status: UNKNOWN ·Phase: NA
-
A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-small Cell Lung Cancer
NCT06161935 ·Status: COMPLETED
-
A Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy
NCT07119190 ·Status: NOT_YET_RECRUITING
-
Segmentectomy for Solid-dominant Lung Cancer
NCT06634966 ·Status: RECRUITING ·Phase: PHASE3
-
SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis
NCT06772363 ·Status: NOT_YET_RECRUITING
-
Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016)
NCT05794724 ·Status: UNKNOWN
-
Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015)
NCT05794711 ·Status: UNKNOWN
-
Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
NCT06216782 ·Status: RECRUITING
-
A Look Back at How Well Interventional Treatments Work for Bronchopleural Fistulas in Patients With Lung Metastases From Osteosarcoma
NCT06927596 ·Status: NOT_YET_RECRUITING
-
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
NCT06617390 ·Status: COMPLETED
-
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
NCT06358222 ·Status: RECRUITING
-
The Establishment and Clinical Application of a Prediction Model of Lung Cancer Distant Metastasis Based on the Genomic Characteristics of Circulating Tumor Cells
NCT04568720 ·Status: UNKNOWN
-
Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy
NCT07256002 ·Status: ACTIVE_NOT_RECRUITING
-
Survival Outcomes of Lung Cancer
NCT03647098 ·Status: RECRUITING
-
Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
NCT06634979 ·Status: RECRUITING ·Phase: NA
-
Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery
NCT06483698 ·Status: RECRUITING
-
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
NCT03926260 ·Status: COMPLETED ·Phase: NA
-
Primary Tumor Resection for M1a Stage Lung Cancer
NCT06547710 ·Status: RECRUITING
-
Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer
NCT06895941 ·Status: WITHDRAWN
-
Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC
NCT07250360 ·Status: COMPLETED
-
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT06255197 ·Status: RECRUITING
-
Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery
NCT00732563 ·Status: COMPLETED ·Phase: NA